EUVIMEDEUVIMED entdecken
Crossref

Secukinumab treatment of psoriatic arthritis in real world: Achievement of fast response results in effective and lasting treatment outcomes

Sina Mackay, Sabine Kugler, Schulz, Daniel, Maximilian Klippstein, Kiltz, Uta, Brandt-Jürgens, Jan, Benjamin Gmeiner, Asmir Vodenčarević, Daniel Peterlik und 6 weitere

Fraunhofer-Publica (Fraunhofer-Gesellschaft) · 01.01.2023

DOI: 10.24406/publica-1947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fraunhofer-Publica (Fraunhofer-Gesellschaft), erschienen am 01.01.2023. Verfasst von Sina Mackay und 17 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Individualized treatment strategies are of high importance in the treatment of patients with chronic immune-mediated diseases such as psoriatic arthritis (PsA). IL17 inhibition has demonstrated good efficacy on all manifestations of PsA but in some patients a lack of efficacy can be observed. To analyze patient characteristics leading to treatment response patterns in PsA patients, data from the German non-interventional study “AQUILA” (Kiltz et al. 2019) was analyzed.

Methods

The non-interventional study “AQUILA” includes, in addition to patients with axial spondyloarthritis, patients with active PsA. In the current analysis patients started treatment within a period of 4 weeks around their baseline visit (V1) and were followed-up over 52 weeks (V2-V6). Response in this cohort was defined as a combination of patient- (PsAID-12) and physician-derived (PhGA) assessments. Patients who reached a state of remission (PsAID-12 ≤ 1.4 and PhGA ≤ 1) or adequate improvement (20% improvement in PsAID-12 and PhGA compared to baseline) at any time during the study period were considered responders. A fast response was defined as reaching at least adequate improvement within the first 8 weeks of treatment (V2), all other responses were considered as late responses.

Results

A cohort of 914 PsA patients was analyzed and divided into 3 subgroups (Table 1). Among fast responders, number of smokers was significantly lower (p=0.009) with a lower median BMI (p=0.004). Fast response was associated with a stronger and longer lasting therapy effect during further study course compared to late response: 50% response (p=0.003), remission state (p=0,019) and measurable response at week 52 (p=0.051) according to the definitions above were observed more often.

Conclusion

Our results show that secukinumab is an effective biologic treatment in PsA patients. As with every available treatment option, its response is dependent on demographics and disease characteristics. The results underline the dependency of fast response on clinical phenotype. Fast responders seem to benefit from both fast alleviation of symptoms and longer lasting treatment effects.

Schlagwörter

secukinumabpsoriatic arthritisIL-17 inhibitionfast responsetreatment responseremissionsmokingbody mass indexbiologic therapynon-interventional study

Zitieren

APA

Mackay, S., Kugler, S., Schulz, Daniel, Klippstein, M., Kiltz, Uta, Brandt-Jürgens, Jan, Gmeiner, B., Vodenčarević, A., Peterlik, D., Wendt, Guillaume, Behrens, Frank, Köhm, M., & :unav (2023). Secukinumab treatment of psoriatic arthritis in real world: Achievement of fast response results in effective and lasting treatment outcomes. Fraunhofer-Publica (Fraunhofer-Gesellschaft). https://doi.org/10.24406/publica-1947

Vancouver

Mackay S, Kugler S, Schulz, Daniel, Klippstein M, Kiltz, et al. Secukinumab treatment of psoriatic arthritis in real world: Achievement of fast response results in effective and lasting treatment outcomes. Fraunhofer-Publica (Fraunhofer-Gesellschaft). 2023. doi:10.24406/publica-1947

BibTeX
@article{Mackay2023,
  author = {Mackay, Sina and Kugler, Sabine and Schulz and Daniel and Klippstein, Maximilian and Kiltz and Uta and Brandt-Jürgens and Jan and Gmeiner, Benjamin and Vodenčarević, Asmir and Peterlik, Daniel and Wendt and Guillaume and Behrens and Frank and Köhm, Michaela and :unav},
  title = {Secukinumab treatment of psoriatic arthritis in real world: Achievement of fast response results in effective and lasting treatment outcomes},
  journal = {Fraunhofer-Publica (Fraunhofer-Gesellschaft)},
  year = {2023},
  doi = {10.24406/publica-1947}
}
Kostenlos starten →